Measurable residual disease driven strategy for one or two infusions of non-viral, transposon-manipulated CARCIK-CD19 cells. A Phase II study in pediatric and adult patients with relapsed/refractory B cell precursor ALL (BCP-ALL) - FT03CARCIK

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2021
This article has no abstract
Epistemonikos ID: 0d782615bc768bf5a2b5b419ca72883f7b73b4ca
First added on: Apr 17, 2025